A retrospective study of the diagnostic accuracy of fine-needle aspiration for breast lesions and implications for future use
Article first published online: 14 OCT 2008
Copyright © 2008 Wiley-Liss, Inc.
Volume 36, Issue 12, pages 855–860, December 2008
How to Cite
Day, C., Moatamed, N., Fimbres, A. M., Salami, N., Lim, S. and Apple, S. K. (2008), A retrospective study of the diagnostic accuracy of fine-needle aspiration for breast lesions and implications for future use. Diagn. Cytopathol., 36: 855–860. doi: 10.1002/dc.20933
- Issue published online: 5 NOV 2008
- Article first published online: 14 OCT 2008
- Manuscript Accepted: 25 JUN 2008
- Manuscript Received: 6 MAR 2008
- fine-needle aspiration;
In recent years, the use of fine-needle aspiration (FNA) in the diagnosis of breast lesions has declined in many institutions. We sought to evaluate the role of FNA for breast lesions and the annual rate of the procedure at our institution over a 4½ year period (May 2002–October 2006). A total of 831 FNAs were performed, with 258 (31%) having histologic follow-up. The number of FNAs obtained was 159 from 5/02 to 4/03, 192 from 5/03 to 4/04, 194 from 5/04 to 4/05, 191 from 5/05 to 4/06, and 95 from 5/06 to 10/06. Each case was placed into one of four categories: nondiagnostic (9%), benign (77.5%), atypical/suspicious (5.5%), or malignant (8%). Surgical tissue was available for 37% of nondiagnostic cases, 22% of benign cases, 80% of atypical/suspicious cases, and 72% of malignant cases. The overall sensitivity and specificity for FNA was 83 and 92% respectively. The overall positive and negative predictive values were 83 and 92% respectively. There were no false-positive cases, indicating a positive predictive value of 100% for a Dx of malignancy. For cases with surgical follow-up, the false-negative rate was 5.4%. Although there is a national trend away from FNAs of breast lesion, this has not been the experience at our institution. Although FNA may not be ideal in the initial evaluation of suspicious lesions, we argue that FNA for clinically benign palpable lesions and recurrent carcinomas has significant value. Diagn. Cytopathol. 2008. © 2008 Wiley-Liss, Inc.